HER2+ Breast Cancer

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.

Frontline T-DXd plus pertuzumab is under FDA priority review for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.

Naoto T. Ueno, MD, PhD, FACP, discusses treatment sequencing considerations in HER2+ advanced or metastatic breast cancer.

T-DXd demonstrated durable systemic and intracranial responses in patients with HER2-positive, -low, and -zero breast cancer brain metastases.

Trastuzumab pamirtecan improved progression-free survival in HER2-positive advanced breast cancer after prior trastuzumab and taxane-based chemotherapy.

GLSI-100 received fast track designation from the FDA for patients with HLA-A*02- and HER2-positive breast cancer after SOC therapy.

Jason Aboudi Mouabbi, MD, discusses neoadjuvant multi-agent chemotherapy in HER2+ breast cancer.

Paolo Tarantino, MD, PhD, discusses the efficacy and safety of adjuvant THP in patients with stage II to IIIA HER2-positive breast cancer.

The VENTANA HER2 (4B5) test earned CE-IVDR approval in Europe to assess HER2 status in metastatic breast cancer and biliary tract cancer.

Neelam V. Desai, MD, discusses the role of first-line CDK4/6 inhibitors in HR-positive, HER2-negative and HER2-positive metastatic breast cancer.

Jason A. Mouabbi, MD, discusses unmet needs and areas requiring further investigation in HER2-positive advanced breast cancer.

Jessica Paulus, ScD, discusses the incorporation of an external control arm into the analysis of a phase 2 trial in HER2-positive breast cancer.

Trastuzumab deruxtecan has been approved in Japan for patients with HR+, HER2-low or -ultralow metastatic breast cancer.

Jessica Paulus, ScD, discusses the development of a real-world control arm to inform the utility of findings from a trial in HER2-positive breast cancer.

Kelly McCann, MD, PhD, discusses the relevance of patient preferences during treatment decision-making for patients with HER2-positive breast cancer.

Ribociclib plus trastuzumab and an AI produced a median PFS of 30.4 months in patients with hormone receptor–positive, HER2-positive breast cancer.

The antibody-drug conjugate SHR-A1811 demonstrated a comparable pCR rate to SHR-A1811/pyrotinib and PCbHP in HER2-positive breast cancer.

Real-world tucatinib-based regimens were effective in different lines for HER2-positive metastatic breast cancer, including after trastuzumab deruxtecan.

Dalpiciclib plus pyrotinib and endocrine therapy was active with a manageable safety profile in patients with ER-positive, HER2-positive advanced breast cancer.

Jessica Paulus, ScD, discusses the clinical implications of using real-world data to add an external control arm to a phase 2 study in HER2+ breast cancer.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.

BB-1701 generated responses with manageable safety in HER2-expressing breast cancer previously treated with an ADC with a topoisomerase I inhibitor.

The novel bispecific antibody TQB2930 plus chemotherapy elicited responses in heavily pretreated HER2-positive breast cancer.

JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.

The FDA granted breakthrough therapy designation to first-line trastuzumab deruxtecan plus pertuzumab in HER2-positive metastatic breast cancer.